UPDATE: Zacks Downgrades Pure Bioscience to Neutral from Outperform on Commercialization Delays
Posted on December 14, 2012 at 13:57 PM EST
Zacks downgraded Pure Bioscience (NASDAQ: PURE ) from Outperform to Neutral with a $1.75 price target. Zacks said, "[W]e are concerned about the slow sales ramp for the Company s SDC products. Although its lead product PURE Hard Surface is increasingly gaining recognition, sales may take longer time to